Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
02/26/02	SEK 0.8440	+4.46%	11,90,967
01/26/01	SEK 0.8080	+1.00%	7,07,328
31/26/31	SEK 0.8000	-4.76%	6,80,209
28/26/28	SEK 0.8400	-0.59%	16,76,168
27/26/27	SEK 0.8450	+1.32%	8,87,200

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 06:13:09 02/09/2026 pm IST			5-day change	1st Jan Change
0.8440 ^SEK	+4.46%		+1.20%	+1.81%

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	16Cr 1.71Cr 1.47Cr 1.38Cr 1.26Cr 2.37Cr 162Cr 2.39Cr 6.37Cr 82Cr 6.41Cr 6.27Cr 273.24Cr	P/E 2026 *	-2.99x	P/E 2027 *	-2.13x
Enterprise Value	15Cr 1.54Cr 1.33Cr 1.25Cr 1.14Cr 2.14Cr 146.17Cr 2.15Cr 5.75Cr 74Cr 5.78Cr 5.66Cr 246.54Cr	EV / Sales 2026 *	4.71x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
08/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW

20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
08/04	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
26/03	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/25/06	Alzinova gets fast track designation from US FDA	RE

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ

1 day	+4.46%
1 week	+1.20%
Current month	+5.50%
1 month	-22.99%
3 months	+77.87%
6 months	+37.24%
Current year	+1.81%

1 week	0.77	0.9
1 month	0.75	1.23
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+4.46%	+1.20%	-36.54%	-73.16%	1.71Cr
LONZA GROUP AG	+0.92%	-0.95%	+3.30%	+17.54%	4.97TCr
REVOLUTION MEDICINES, INC.	+2.09%	-0.71%	+452.73%	+498.77%	4.5TCr
IQVIA HOLDINGS INC.	-1.09%	-0.41%	+35.40%	+15.17%	4.25TCr
BEONE MEDICINES AG	-0.26%	-4.71%	+17.19%	+71.67%	4.08TCr
CELLTRION, INC.	-0.48%	-0.84%	+16.25%	+49.80%	3.29TCr
ASCENDIS PHARMA A/S	-1.06%	+2.87%	-	-	1.71TCr
MEDPACE HOLDINGS, INC.	-1.81%	-5.02%	+22.65%	+113.24%	1.63TCr
EUROFINS SCIENTIFIC SE	+1.03%	-0.71%	+17.75%	+27.24%	1.44TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.05%	-5.14%	+72.89%	+34.69%	1.35TCr
Average	+0.17%	-2.63%	+66.85%	+83.88%	2.72TCr
Weighted average by Cap.	+0.02%	-2.27%	+97.52%	+122.37%

	2026 *	2027 *
Net sales	3.14Cr 32.68L 28.19L 26.52L 24.16L 45.43L 31Cr 45.68L 1.22Cr 16Cr 1.23Cr 1.2Cr 52Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.4Cr -6L -17.32L -2.24Cr -17.42L -17.04L -7.43Cr	-7.7Cr -80.27L -69.24L -65.13L -59.34L -1.12Cr -76Cr -1.12Cr -3Cr -39Cr -3.01Cr -2.95Cr -128.5Cr
Net Debt	-1.6Cr -16.68L -14.39L -13.53L -12.33L -23.19L -16Cr -23.31L -62.28L -8.05Cr -62.62L -61.27L -27Cr	-1.9Cr -19.81L -17.09L -16.07L -14.64L -27.53L -19Cr -27.68L -73.95L -9.56Cr -74.37L -72.75L -32Cr